AzTrials
AzTrials

Schizophrenia and Schizophrenia Spectrum PsychosisNCT07234708

Feeling Safe Study

A study testing Sentirnos Seguros in people with Schizophrenia and Schizophrenia Spectrum Psychosis, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Sentirnos Seguros
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
1 siteSpain
Study dates
1 Jul 2025to 1 May 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men and women aged 18 years and older
  • Diagnosis of schizophrenia spectrum disorders and other psychotic disorders according to DSM-5
  • Score ≥ 4 on the delusions item of the Positive and Negative Syndrome Scale (PANSS)
  • Presence of ideas of persecution with a degree of conviction > 60% in the last 3 months

Who cannot join

  • Presence of intellectual disability
  • Meet DSM-5 criteria for other mental health disorders, except for substance-related and addictive disorders

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Eva Grasa, PhD Psychologist contact

+34 93 553 78 40

egrasa@santpau.cat

Spain1 site, 1 recruiting
  • Department of Psychiatry. Hospital Santa Creu i Sant Pau

    Barcelona, 08025

    Eva Grasa, PhD Psychologist, +34 93 553 78 40, egrasa@santpau.cat

    Recruiting

Other trials in Spain

About this study

Official title: Feeling Safe: Feasibility and Acceptability Study Evaluating a New Psychological Intervention for People With Psychosis and Positive Delusional Symptoms

The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.

The main questions it aims to answer are:

  • Study participants will report high levels of acceptability and satisfaction with the Sentirnos Seguros programme.
  • The Sentirnos Seguros intervention will be beneficial for participants at a clinical and functional level, with higher scores in the post-treatment phase compared to the pre-treatment phase.
Read the detailed description

This is a prospective, non-randomised feasibility pilot study with a before-and-after design.

The aims of the study are:

  1. Assess the feasibility, acceptability, and satisfaction after receiving the Sentirnos Seguros programme in people with schizophrenia spectrum disorder and positive delusional symptoms.
  2. Evaluate the clinical and functional benefits and safety of the Sentirnos Seguros programme.
Being tested
Sentirnos Seguros
Keywords
Feeling Safe, Schizophrenia, Acceptability, Feasibility
Medical subject headings
Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sentirnos SegurosOther

    The Sentirnos Seguros (Feeling Safe) programme is modular, personalised and includes the patient's preferences. The following modules are offered: improving sleep, reducing worry, increasing self-confidence, reducing the impact of voices, and feeling safe enough.

Study groups in NCT07234708
Study groupRoleWhat they receive
InterventionExperimentalNot described
Receives: Other: Sentirnos Seguros

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Compliance related to the total number of successful appointments made

    Compliance will be assessed by calculating the frequency of successful appointments from baseline to 6 months (end of therapy)

    Measured: From baseline to 6 months (end of therapy)

  2. Number of drop-outs

    The number of drop-outs will be assessed by calculating the proportion of participants who do not complete the study protocol

    Measured: From baseline to 6 months (end of treatment)

  3. Acceptability, measured with an ad hoc questionnaire

    Acceptability with the intervention will be assessed by an ad hoc questionnaire to measure the dimensions of acceptability: perceived utility, perceived ease of use, barriers, and intention to use

    Measured: From baseline to 6 months (end of the treatment)

  4. Satisfaction with the intervention, measured with the Client Satisfaction Questionnaire (CSQ-8)

    Satisfaction with the intervention will be assessed using the CSQ-8. A 4-point Likert scale is used to rate each item (1 = very dissatisfied; 4 = very satisfied), yielding a total score ranging from 8 to 32. A low score (close to 8) indicates low satisfaction with the services received, and a high score (close to 32) indicates high satisfaction with them.

    Measured: From baseline to 6 months (end of the treatment)

Secondary outcomes (14)
  1. Change in the severity of psychotic symptoms, measured with the Positive and Negative Syndrome Scale (PANSS)

    The severity of psychotic symptoms will be assessed using the PANSS. This scale includes 30 items (7 for positive symptoms, 7 for negative symptoms, and 16 for general psychopathology). A 7-point Likert scale is used to rate each item (1 = not present; 7= most severe). The total score is the sum of all items. No specific cut-off scores have been established for the PANSS. The higher the score, the greater the clinical severity.

    Measured: Changes in baseline scores at 6 months

  2. Change in severity of hallucinations and delusions, measured with the Psychotic Symptom Rating Scales (PSYRATS)

    The severity of hallucinations and delusions will be assessed using the PSYRATS. It consists of two subscales, one for hallucinations and one for delusions, each with 17 items, with Likert-type responses ranging from 0 to 5. The final score is obtained by adding the scores for each item. It can range from 0 to 44. No specific cut-off scores have been established for the PSYRATS. The higher the score, the more severe the hallucinations/delusions.

    Measured: Changes in baseline scores at 6 months

  3. Change in depression severity, measured with the Calgary Depresión Scale for Schizophrenia (CDSS)

    The depression severity is assessed using the CDSS. This scale includes 9 items that are scored with a Likert scale that ranges from 0 (absent) to 3 (severe). The total score is the sum of all items. The higher the score, the greater the clinical severity. To identify the absence/presence of depression, a score ≥ 5 is the cut-off point.

    Measured: Changes in baseline scores at 6 months

  4. Change in the delusional conviction severity measured with the delusional conviction-analogue visual scale (DC-VAS)

    Change in the delusional conviction severity will be assessed using the DC-VAS. This scale rates the degree of conviction of the delusional idea from 0 to 10.

    Measured: Changes in baseline scores at 6 months

  5. Change in core beliefs, measured with the Brief Core Schema Scales (BSCC)

    The change in core beliefs will be assessed using the BCSS. This scale assesses an individual's core beliefs about themselves and others using a 5-point Likert scale (0-4). It comprises 24 items, yielding four scores: negative-self, positive-self, negative-others, and positive-others. Each score is based on six items. No specific cut-off scores have been established for the BCSS, scores are generally interpreted within a range. Higher scores generally indicate a greater endorsement of the beliefs represented by that subscale.

    Measured: Changes in baseline scores at 6 months

  6. Change in safety behaviour severity, measured with the Safety Behaviour Questionnaire (SBQ)

    The safety behaviour severity will be assessed using the SBQ. This scale consists of 56 items rated on a 4-point Likert scale, where 0 = never and 3 = always. Specific cut-off scores haven't been established for the SBQ. Higher scores indicate greater frequency of use of safety behaviours.

    Measured: Changes in baseline score at 6 months

  7. Change in paranoid ideation, measured with the Spanish Green Paranoid Thought Scale (S-GPTS)

    The change in paranoid ideation will be assessed using the S-GPTS. This scale consists of a total of 32 items rated on a 5-point Likert scale from 1 (Not at all) to 5 (Completely). The items are grouped into two scales of 16 items. Scale A assesses social reference ideas relevant to paranoia, while Scale B assesses persecutory thoughts. Scores on each scale range from 16 to 80 points, with higher scores reflecting a greater level of paranoid thinking. No cut-off points have been established.

    Measured: Changes in baseline scores at 6 months

  8. Change in functioning severity, measured with the Personal and Social Performance scale (PSP)

    The change in functioning severity will be assessed using the PSP scale. The PSP scale evaluates four domains: Socially Useful Activities, Personal and Social Relationships, Self-Care, and Disturbing and Aggressive Behaviours. Each domain is rated on a 6-point severity scale, which is then converted into a 10-point band score for that domain. A total score is derived from the four domain scores, resulting in a single score between 1 and 100. No cut-off score is available. Higher scores indicate better functioning across all domains, with more severe functional difficulties reflected in lower scores.

    Measured: Changes in baseline scores at 6 months

  9. Change in self-perceived functionality severity, measured with the Self-perceived Functionality in people with Psychotic disorders (FAP-10)

    The change in self-functionality will be assessed using the FAP-10. This questionnaire includes 10 items that are scored on a Likert scale ranging from 4 (Always) to 0 (Never). The total score is the sum of the scores for each item. The total score ranges from 0 (poor functionality) to 40 (excellent functionality).

    Measured: Changes in baseline scores at 6 months

  10. Change in quality of life, measured with the Quality of Life Index (QLI-sp)

    The change in quality of life will be assessed using the QLI-sp. It is a 10-item questionnaire that assesses various aspects of health-related quality of life. It is scored on a scale of 1 to 10 points, with a higher score corresponding to a better quality of life. No cut-off scores are available.

    Measured: Changes in baseline scores at 6 months

  11. Change in recovery, measured with the Questionnaire about the Process of Recovery (QPR)

    The change in recovery will be assessed using the QPR. It is a 15-item scale. Each item is rated on a 5-point Likert scale, from 0 (strongly disagree) to 4 (strongly agree), and the items are added together to obtain a total recovery score. Higher scores indicate greater recovery. No cut-off scores are available.

    Measured: Change in baseline scores at 6 months

  12. Change in clinic insight, measured with the Scale Unawareness of Mental Disorders (SUMD)

    The change in clinic insight will be assessed using the SUMD. It consists of three items that explore the degree of insight a person has into their mental disorder, the effects of medication, and the social consequences. Each item is scored from 0 to 5, where 0 indicates that the item is not relevant or cannot be assessed, and 5 indicates a lack of awareness. No cut-off points are available.

    Measured: Changes in baseline scores at 6 months

  13. Change in cognitive insight, measured with the Beck Cognitive Insight Scale (BCIS)

    The change in cognitive insight will be assessed using the BCIS. The BCIS assesses cognitive insight, specifically self-reflectiveness and self-certainty, in individuals with psychosis. It's a 15-item self-report measure where participants rate their agreement with statements on a scale of 0 to 3. The BCIS yields two subscale scores (self-reflectiveness and self-certainty) and a composite Reflectiveness-Certainty (R-C) index score. The R-C index is calculated by subtracting the self-certainty score from the self-reflectiveness score. Higher R-C index scores indicate greater cognitive insight. Cut-off scores: low cognitive insight, scores of 3 and below; moderate cognitive insight, scores of 4 to 9; and high cognitive insight, scores of 10 and above.

    Measured: Changes in baseline scores at 6 months

  14. Presence of adverse events, measured with an ad hoc clinical interview

    Safety during the intervention will be assessed by collecting the presence of adverse events using an ad hoc clinical interview

    Measured: From baseline to 6 months (end of the intervention)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2025
  2. Study start1 Jul 2025
  3. Primary completion1 Mar 2028 (estimated)
  4. Study completion1 May 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
35 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07234708
Sponsor's protocol ID
IIBSP-SEG-2024-186
Status last verified
Nov 2025
First submitted
28 Jul 2025
Last updated
21 Nov 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Sentirnos Seguros in people with Schizophrenia and Schizophrenia Spectrum Psychosis, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Eva Grasa, PhD Psychologist (+34 93 553 78 40, egrasa@santpau.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Compliance related to the total number of successful appointments made (time frame: From baseline to 6 months (end of therapy)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in